The pricing of pharmaceuticals, and in particular whether prices are “too high” or “excessive”, is a contentious topic in the EU, as elsewhere. What is “excessive” in this context and what other antitrust arguments are used in this key sector? Paul Csiszar, Director, European Commission, DG Competition and Bill Batchelor, Partner, Skadden, Arps, Slate, Meagher & Flom LLP join Matthew Hall and John Roberti to discuss recent cases and policy directions, including several cases based on allegations of abuse of dominance by pharmaceutical companies. Listen to this episode to learn more about how EU competition/antitrust law can be one part of the toolbox available to investigate and deal with the issue of excessive pricing in pharmaceuticals.

Paul Csiszar, Director, European Commission, DG Competition

Paul Csiszar, Director, European Commission, DG Competition and Bill Batchelor, Partner, Skadden, Arps, Slate, Meagher & Flom LLP

Related Links:

European Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines

UK Competition and Markets Authority: Phenytoin sodium capsules: suspected unfair pricing

European Court of Justice: Case C-307/18 Generics (UK) and Others

UK Competition and Markets Authority: Remicade: alleged abusive discount scheme

Hosted by:

John Roberti, Partner, Allen & Overy, LLP and Matthew Hall, Partner, McGuireWoods London LLP